$4.95 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter

Wall Street brokerages expect TherapeuticsMD Inc (NASDAQ:TXMD) to post $4.95 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for TherapeuticsMD’s earnings, with the highest sales estimate coming in at $5.86 million and the lowest estimate coming in at $4.20 million. TherapeuticsMD reported sales of $4.40 million in the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The business is expected to report its next quarterly earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $4.95 million for the current year, with estimates ranging from $17.20 million to $24.17 million. For the next fiscal year, analysts anticipate that the business will report sales of $110.60 million per share, with estimates ranging from $68.00 million to $143.09 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow TherapeuticsMD.

Several equities analysts have recently commented on TXMD shares. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a research report on Wednesday, May 10th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $15.00 target price on shares of TherapeuticsMD in a research report on Monday, April 17th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a research report on Monday, April 24th. Finally, Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, June 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. TherapeuticsMD currently has a consensus rating of “Buy” and an average price target of $18.40.

ILLEGAL ACTIVITY WARNING: “$4.95 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.chaffeybreeze.com/2017/07/30/4-95-million-in-sales-expected-for-therapeuticsmd-inc-txmd-this-quarter-updated-updated-updated.html.

A number of institutional investors have recently modified their holdings of TXMD. Raymond James Financial Services Advisors Inc. raised its position in shares of TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the last quarter. Greenwood Capital Associates LLC increased its stake in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp increased its stake in shares of TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares during the last quarter.

Shares of TherapeuticsMD (NASDAQ TXMD) traded up 3.42% on Friday, reaching $5.45. 648,227 shares of the company’s stock traded hands. The company has a 50 day moving average of $4.62 and a 200-day moving average of $5.62. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.72. The stock’s market capitalization is $1.11 billion.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply